Parmax Pharma Limited's mandatory open offer by acquirers Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with ten persons acting in concert (PACs), commences on July 30, 2026, with tendering closing on August 12, 2026. The offer price of ₹42.80 per equity share represents a significant discount to the prevailing market price of ₹102.83 recorded on July 24, 2026, creating a material arbitrage opportunity for public shareholders. The acquisition aims to consolidate control, with the acquirer group targeting a post-offer holding of 94.34% of the expanded voting capital, effectively reducing public shareholding to 5.66%.

The open offer, mandated under Regulations 3(1) and 4 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, seeks to acquire up to 23,46,250 fully paid-up equity shares, representing 26.00% of the expanded voting share capital. Fedex Securities Private Limited serves as the Manager to the Open Offer. The Committee of Independent Directors (IDC) unanimously recommended the offer as fair and reasonable on July 25, 2026, citing compliance with regulatory pricing parameters despite the market premium. The recommendation was published in newspapers on July 27, 2026, and the Offer Opening Pre-Offer Advertisement was issued on July 29, 2026.

Offer Timeline and Key Dates

Public shareholders must adhere to the strict schedule outlined in the Letter of Offer dated July 21, 2026. The tendering period allows shareholders to submit their bids through the BSE Acquisition Window.

Shareholders holding shares in demat form must tender through their selling brokers before market hours close on the last day of the tendering period. Those holding physical shares must deliver original certificates and completed forms to the Registrar to the Offer, Purva Share Registry (India) Private Limited, within two days of the offer closing date.

Shareholding Structure and Control Shift

The transaction marks a complete change in control for Parmax Pharma. The existing promoters, including Akesh Mahasukhlal Gopani and Vipul Mahasukhlal Gopani, will cease to be promoters following the Share Purchase Agreement (SPA) and preferential issue. The new promoter group will comprise Dhiren Chandulal Shah (Acquirer 1), Sunil Chinubhai Shah (Acquirer 2), Hiren Pravin Doshi (PAC 2), and Umang Alkesh Gosalia (PAC 9).

The acquirer group already holds 27.20% of the current equity share capital. Through the SPA, preferential issue, and this open offer, they will aggregate 85,13,432 shares. The remaining public shareholders will retain only 5,10,599 shares, assuming full acceptance of the open offer.

What the Numbers Show

The most critical aspect for investors is the wide divergence between the offer price and the market price. While the IDC deemed ₹42.80 fair based on historical trading averages and negotiated prices, the recent market price of ₹102.83 suggests strong investor confidence or speculative activity unrelated to the takeover mechanics. Tendering shares at ₹42.80 implies a realized loss of approximately 58% compared to the July 24 market close. However, shareholders who do not tender will face a highly concentrated ownership structure, potentially impacting liquidity and future price discovery as public float drops below 6%. The acquirers have undertaken to maintain minimum public shareholding requirements under SEBI LODR regulations if the float falls below 25%, likely through further dilution or open market purchases within 12 months.

Regulatory Compliance and Approvals

No statutory approvals are currently required to complete the offer, except for the in-principle approval from BSE Limited, which was applied for on June 9, 2026, and remains under process. The offer cannot be withdrawn even if this approval is delayed, provided no other statutory refusals occur. SEBI issued its observations on the Draft Letter of Offer on July 14, 2026, which have been incorporated into the final Letter of Offer. The escrow amount has been secured via a fixed deposit with a lien marked in favor of the Manager to the Offer.

Parmax Pharma shareholders have approved the issuance of equity shares and convertible warrants to non-promoter investors through a preferential allotment. The resolutions were passed during an Extraordinary General Meeting (EGM) held on July 2, 2026, via video conferencing. These approvals enable the company to restructure its capital base and raise funds to support future growth initiatives, with all four proposed resolutions receiving the requisite majority.

The meeting, chaired by Managing Director Mr. Umang Alkesh Gosalia, commenced at 11:30 a.m. and concluded at 11:57 a.m. Proceedings were conducted in compliance with the Companies Act, 2013, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Purva Sharegistry (India) Private Limited facilitated the electronic voting process, which was open for remote e-voting from June 29 to July 1, 2026, and during the meeting itself. Shreyans Jain, Practicing Company Secretary, served as the scrutinizer.

Resolutions Passed

The shareholders passed one ordinary resolution and three special resolutions. The ordinary resolution authorized an increase in the authorised share capital and the consequent alteration of the capital clause of the memorandum of association. A special resolution was adopted to replace the existing articles of association with a new set, aligning internal regulations with current governance standards.

Preferential Capital Issuance

Two special resolutions sanctioned the preferential issuance of securities to non-promoter investors. The first authorized the issuance of 31,37,586 equity shares, while the second approved the issuance and allotment of 21,45,145 convertible warrants. Both issuances are on a private placement basis.

The detailed scrutinizer's report confirms that all resolutions were passed with the required majority, with 23,36,153 votes cast in favour of the resolutions.